Skip to main content
NewslettersWatchlist

Avalo Therapeutics Inc(AVTX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low10.09
Day High10.93
Open:10.61
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Business Wire
Origin Materials and Avantium to Accelerate the Mass Production of FDCA and PEF for Advanced Chemicals and Plastics
Globe Newswire
Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates
Globe Newswire
Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)
Globe Newswire
Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics
Globe Newswire
Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split
Globe Newswire
Avalo to Present at the 2022 Jefferies Healthcare Conference
Globe Newswire
Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA)
Globe Newswire
Avalo to Present at the H.C. Wainwright Global Life Sciences Conference
Globe Newswire
Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates
Globe Newswire
Avalo to Present at Oppenheimer's 32nd Annual Healthcare Conference
Globe Newswire
Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates
Globe Newswire
Avalo Therapeutics Announces Leadership Transition
Globe Newswire
Avalo Therapeutics to Present at the 2022 BIO CEO and Investor Conference
Globe Newswire
Avalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer
Globe Newswire
Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event
Globe Newswire
Avalo Therapeutics to Host Virtual Investor Day on January 6, 2022
Globe Newswire
Avalo to Present at Two Upcoming Conferences
Globe Newswire
Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates
Globe NewsWire
Avalo to Present at the 2021 Cantor Virtual Global Healthcare Conference
Globe NewsWire
Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares
Globe NewsWire
Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock
Globe NewsWire
Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Globe NewsWire
Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.

Profile

Avalo Therapeutics Inc. is a clinical-stage precision medicine company which discovers, develops and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology and rare genetic diseases. Avalo Therapeutics Inc., formerly known as Cerecor, is based in WAYNE, Pa.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.